Skeletal Muscle Fibrosis in Pancreatic Cancer Patients with Respect to Survival.

Autor: Judge SM; Department of Physical Therapy, University of Florida Health Science Center, Gainesville, FL., Nosacka RL; Department of Physical Therapy, University of Florida Health Science Center, Gainesville, FL., Delitto D; Department of Surgery, College of Medicine, University of Florida Health Science Center, Gainesville, FL., Gerber MH; Department of Surgery, College of Medicine, University of Florida Health Science Center, Gainesville, FL., Cameron ME; Department of Surgery, College of Medicine, University of Florida Health Science Center, Gainesville, FL., Trevino JG; Department of Surgery, College of Medicine, University of Florida Health Science Center, Gainesville, FL., Judge AR; Department of Physical Therapy, University of Florida Health Science Center, Gainesville, FL.
Jazyk: angličtina
Zdroj: JNCI cancer spectrum [JNCI Cancer Spectr] 2018 Jul; Vol. 2 (3), pp. pky043. Date of Electronic Publication: 2018 Aug 06.
DOI: 10.1093/jncics/pky043
Abstrakt: Background: Cancer cachexia is a catabolic condition characterized by skeletal muscle wasting, consequent to tumor burden, which negatively impacts tolerance to cancer therapies and contributes to increased mortality. Partly because of the limited knowledge of the underlying mechanisms of cancer cachexia derived from human studies, however, the ability to therapeutically intervene remains elusive. The purpose of the current study was therefore to better define the phenotype of skeletal muscle obtained from patients with pancreatic ductal adenocarcinoma (PDAC), which has one of the highest rates of cachexia.
Methods: Morphological analyses were performed on rectus abdominis muscle biopsies obtained from resectable PDAC patients undergoing tumor resection surgery (N = 20) and from weight-stable non-cancer control subjects undergoing benign abdominal surgery (N = 16). PDAC patients with a body weight loss of greater than 5% during the previous 6 months were considered cachectic (N = 15). Statistical tests were two sided.
Results: Skeletal muscle from cachectic PDAC patients had increased collagen content compared with non-cancer control subjects (1.43% vs 9.66%, P  = .0004, Dunn test). Across all PDAC patients, collagen content positively correlated with body weight loss (P  = .0016, r  = 0.672), was increased in patients with lymph node metastasis ( P  = .007, Mann-Whitney U test), and was associated with survival on univariate (HR = 1.08, 95% confidence interval [CI] = 1.02 to 1.04, P  = .008) and multivariable analyses (HR = 1.08, 95% CI = 1.00 to 1.17, P  = .038). Cachectic PDAC patients also displayed increased lipid deposition (2.63% vs 5.72%, P  = .042), infiltration of CD68+ macrophages (63.6 cells/mm 2 vs 233.8 cells/mm 2 , P  = .0238), calcium deposition (0.21% vs 2.51%, P  = .030), and evidence of deficient cellular quality control mechanisms (Mann-Whitney U test). Transcriptional profiling of all patients supported these findings by identifying gene clusters related to wounding, inflammation, and cellular response to TGF-β upregulated in cachectic PDAC patients compared with non-cancer control subjects.
Conclusions: To our knowledge, this work is the first to demonstrate increased collagen content in cachectic PDAC patients that is associated with poor survival.
Databáze: MEDLINE
Externí odkaz: